About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
In three case histories, patients” sprue-like symptoms improved when olmesartan (Benicar) therapy was withheld.
Tran H. Tran, PharmD, BCPS; and Hanlin Li
Compounding and Tracing Provisions Seek to Improve Quality of Drug Supply
The Drug Quality and Security Act is intended to prevent the sale of contaminated compounded agents, but the way in which facilities will be regulated is still unclear. Many safeguards will need to be implemented.
Are They Worth the Risk?
Dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) offer better efficacy over warfarin, and minimal monitoring is needed. However, there is no effective reversal agent, these new agents are not indicated for all patients, and there is limited information available about drug–drug and drug–disease interactions.
Hira Shafeeq, PharmD, BCPS; and Tran H. Tran, PharmD, BCPS
Agents for Hypertension, Heart Failure, and Acute Myocardial Infarction
Topics include medications used in hypertension, heart failure, renal dysfunction, and myocardial infarction.
Following the guidelines for standard order sets minimizes incorrect prescribing.
Matthew Grissinger, RPh, FaScP
Pharmacists want the FDA to standardize REMS programs.
FDA approvals, drug indications, and updates
Obinutuzumab (Gazyva) for chronic lymphocytic leukemia; ibrutinib (Imbruvica) for mantle-cell lymphoma; and sofosbuvir (Sovaldi) for chronic hepatitis C infection
Marvin M. Goldenberg, PhD, RPh, MS
A Novel Agent for the Treatment of Actinic Keratoses
Brooke Fidler, PharmD; and Tamara Goldberg, PharmD, BCPS